Full-Time

Workday Operations Specialist

People Services

Updated on 9/12/2026

Deadline 9/19/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
People & HR (1)
Required Skills
Data Visualization
Data Structures & Algorithms
ServiceNow
Workday HRIS
RDBMS
Word/Pages/Docs
Excel/Numbers/Sheets

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • Eight to ten years of first-hand experience in a human resources role, preferably in an international multicultural environment.
  • Broad understanding of human resources processes and activities.
  • Computer literacy and familiarity with human resources and human capital management tools and systems such as Workday and ServiceNow.
  • Advanced proficiency in Microsoft Office Suite, including Excel and Word.
  • Ability to interact with internal and external clients professionally.
  • Ability to work collaboratively across teams and with People Services frontline teams using an end-to-end mindset.
  • A graduate or master's degree in human resources or business administration.
  • Excellent spoken and written English.
Responsibilities
  • Administer organization and employee and contractor data for SBU Europe, France, and North America according to service-level agreements.
  • Create, update, activate, deactivate, and delete global master data for organizations, positions, employees, and contractors.
  • Manage employee human resources queries using provided procedures and knowledge-base articles.
  • Record cases and resolution progress in the case-management tool.
  • Provide verbal and written customer service for People Services queries.
  • Develop standards, guidelines, and structures for storing, organizing, and accessing data using relational databases and data warehouses.
  • Collaborate with Automation, ELC and Technology, and ITS teams to manage and resolve problems and develop initiatives that improve user experience for stakeholders and customers.
  • Propose solutions and strategies for business challenges.
  • Present information using data-visualization techniques.
  • Maintain organization, position, employee, and contractor data in Workday for specified Sanofi entities.
  • Prepare complex, high-impact global Workday reports and manage high-impact data involving large employee populations or multiple groups.
  • Monitor data quality in Qlik Sense and Workday, identify potential issues, and take proactive measures.
  • Lead and coordinate transformation-related projects.
  • Analyze large amounts of information to identify trends and patterns.
  • Test and ensure that interfaces between Workday and connected systems function correctly.
  • Act as a liaison with Human Resources, Payroll, Benefits, Finance, Partnership Resources, Information Technology, and other groups regarding human resources systems.
  • Execute activities in compliance with Sanofi policies, guidelines, global core-model requirements, and operational key performance indicators.
  • Develop expert knowledge of in-scope activities and local knowledge of in-scope entities.
  • Resolve high-priority and business-critical ServiceNow incidents, service requests, and change requests through root-cause analysis.
  • Manage complex global compensation corrections and troubleshoot configuration, process, and data issues.
  • Manage robotic process automation subject-matter-expert activities, including daily monitoring, finance requests, and access management.
  • Own development activities with the automation and L4 AIMS teams.
  • Investigate and resolve complex recruitment cases involving job applications, job requisitions, referral validation, and blocking events for rehires.
  • Support exit-module processes, including canceling exit interviews and ending contracts.
  • Provide expert support for employee exit processes, including rescinds, contract amendments, termination corrections, and process exceptions.
  • Support global reorganizations by conducting organizational impact assessments and validating structural changes in OrgStudio.
  • Identify process-improvement opportunities by eliminating redundant activities.
  • Update country manuals, work instructions, and standard operating procedures as new cases and information arise.
Desired Qualifications
  • First-hand human resources experience in an international multicultural environment.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.